USFDA approves Strides Shasun's HIV drug
15 March 2018 | News
The product will be manufactured at the company's oral dosage facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market.
Image credit- livestrong.com
Bengaluru based pharmaceutical company Strides Shasun has received approval from the US health regulator for its generic Efavirenz tablet USP, 600mg used for treatment of HIV Type-1 infected adults and adolescents.
The product will be manufactured at the company's oral dosage facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market.
Efavirenz Tablet is a generic version of Sustiva Tablets of Bristol-Myers Squibb Company.
According to IQVIA data, the US market for Efavirenz Tablets USP, 600 mg is approximately $115 million and Strides is only the second generic company to get the approval for the product under the para IV route.
